Patents Assigned to Oncotyrol Center for Personalized Cancer Medicine GMBH
  • 3-AMINO-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AS CYCLIN DEPENDENT KINASE INHIBITORS
    Publication number: 20200247809
    Abstract: The present invention relates to 3-amino-pyrazolo[3,4-d]pyrimidin-4-ones particularly useful as cyclin dependent kinase (CDK) inhibitors, pharmaceutical compositions comprising the same and the use thereof in particular in the prophylaxis and/or treatment of cancer and other proliferative diseases. Furthermore the present invention relates to processes for the synthesis of said 3-amino-pyrazolo[3,4d]pyrimidin-4-ones and intermediates to be used in the processes of the present invention.
    Type: Application
    Filed: November 29, 2017
    Publication date: August 6, 2020
    Applicants: Oncotyrol Center for Personalized Cancer Medicine GMBH, Vichem Chemie Kutató Korlátolt Felelösségü Társaság
    Inventors: Winfried Wunderlech, Lukas A. Huber, Johann Jakob Leban, János Pató, László Örfi, Wáczek Frigyes, Péter Bánhegyi, Anna Sípos, Csaba Szántai-kis
  • Medical intervention in haematological cancers
    Patent number: 8501734
    Abstract: The present invention relates to the medical and pharmaceutical use of substituted 1H-imidazo[4,5-c]quinolin-4-amines, in particular Imiquimod® and Gardiquimod®, alone or preferably in combination with Akt inhibitors, in particular with Akti1/2 and AktX, and most preferably with Akti1/2, in the treatment, prevention and/or amelioration of haematological cancers, in particular multiple myeloma disorders or B-cell disorders, and most particular in the therapy of multiple myeloma.
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: August 6, 2013
    Assignee: Oncotyrol-Center for Personalized Cancer Medicine GmbH (Ltd.)
    Inventors: Lukas Huber, Simon Schnaiter, Inge Tinhofer, Karin Jöhrer, Richard Greil